Contents
On this page
- Definition of a patient-reported outcome
- Size of the existing instrument pool
- Generic and condition-specific instruments
- Profile and index measures and their analytical implications
- Fixed questionnaires, item banks and computer-adaptive testing
- Selection of an existing instrument
- Limitations of instrument catalogues
- Reporting instrument selection in the methods section
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · PRO instrument types
Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences
Far more patient-reported outcome instruments exist than most researchers realise, and the type selected constrains the analyses and claims available afterwards. Three choices are decisive: generic or condition-specific, profile or index, and fixed-length or item bank. These choices should be made before data collection, because none of them can be corrected later.
A PRO instrument is not a questionnaire selected for convenience. It is a measurement decision that determines which comparisons are available, whether the results can enter an economic model, and whether reviewers will accept that the intended construct was measured. Churruca and colleagues, reviewing the field in Health Expectations, screened 6,453 citations and found 315 instruments meeting their criteria, which indicates that for almost every research question the default assumption should be that a validated instrument already exists. This article describes how the instrument types differ and how to choose between them.
Learning objectives
- The scope of the FDA definition of a patient-reported outcome, including what it excludes
- The size of the existing instrument pool, comprising 315 patient-reported outcome measures (PROMs) from 6,453 screened citations, and the sources to consult before developing a new instrument
- The three principal axes of instrument choice: generic vs condition-specific, profile vs index, fixed-length vs item bank
- Why a profile measure cannot be used in a cost-utility analysis, and why an index cannot localise an effect
- The appraisal of a candidate instrument against the COSMIN taxonomy before its adoption
- The information a methods paragraph must state so that a reviewer can evaluate the instrument rather than accept it on trust
Common misconceptions
- “Generic measures are weaker than condition-specific ones.” Generic and condition-specific measures address different questions. Generic instruments allow comparison across conditions and populations, whereas condition-specific instruments are usually more sensitive to change within a single condition. Churruca and colleagues found that only 39 of 315 instruments were generic, which indicates that the comparable measure, rather than the specific one, is the scarcer resource.
- “Any validated instrument will do for my population.” Validation is a property of an instrument in a population and for a purpose, not a permanent attribute. Messick advanced this argument in American Psychologist four decades ago, and it has not been superseded.
- “A high Cronbach’s alpha means the instrument is good.” Sijtsma, in Psychometrika, argues that alpha is of very limited usefulness even as a reliability estimate, and Cortina had already set out in the Journal of Applied Psychology why it is not a measure of unidimensionality.
- “If it is published, it is in use.” Of the 315 instruments Churruca and colleagues identified, 270 (85.7%) appeared in subsequent research but only 51 (16.2%) had any traceable report of clinical or policy use, and 45 showed no evidence of subsequent use at all.
- “Shortening an instrument is a harmless practical adjustment.” Removing items changes the construct being measured and invalidates the validation evidence cited for the instrument. Rothman and colleagues, in Value in Health, set out the properties that must be re-established after modification.
Definition of a patient-reported outcome
The operative definition is the FDA’s: a patient-reported outcome is any report of the status of a patient’s health condition that comes directly from the patient, without interpretation by a clinician or anyone else 1. The decisive phrase is without interpretation. A clinician-rated severity scale is not a PRO. A proxy report by a caregiver is not a PRO, whatever its merits for a population who cannot self-report. An observer-completed instrument scored from a patient interview is not a PRO either, even where every item is about the patient’s own experience.
The distinction matters in a manuscript because the label carries claims. Describing an observer-rated scale as a patient-reported outcome asserts an independence from clinician judgement that the data do not possess, and a reviewer familiar with the instrument will identify the error. Where a proxy or observer version of an instrument that also has a self-report form is used, the version should be named explicitly and its use justified.
The FDA guidance also makes a claim about sequence that underlies the remainder of this page: content validity must be established first, because no amount of later psychometric testing can repair an instrument that does not measure the intended construct 1. Four groups of measurement properties are then reviewed. That sequence is examined in detail in the companion page on developing and evaluating a PRO instrument.
Size of the existing instrument pool
Before an instrument type is chosen, the size of the existing pool should be established. Churruca and colleagues, in Health Expectations, screened 6,453 citations and identified 315 PROMs meeting their inclusion criteria 2. Of those, 39 were generic and the remainder condition-specific. The largest condition clusters were musculoskeletal, with 42 instruments, and cancer, with 32.
These figures have a clear implication. For a common condition in a well-studied area, the practical problem is not finding an instrument but choosing among a dozen overlapping ones and justifying the choice. For a narrow condition, a rare disease or an outcome that crosses conditions, the pool may genuinely be empty, and it is in this situation that development is defensible.
The pool is also unevenly distributed, which may warrant acknowledgement among a study’s limitations. Churruca and colleagues found that 147 instruments (46.8%) originated in the United States, 81 (25.8%) in the United Kingdom, 29 (9.2%) in Canada and 12 (3.8%) in Australia 2. Where the study population does not resemble the development sample, cross-cultural validation evidence should be sought specifically, and the paper should report what was found, including when nothing was found.
The size and shape of the existing instrument pool. Source: Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, Leahy CJ, Braithwaite J. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expectations.
Generic and condition-specific instruments
A generic instrument measures health status or quality of life in terms that apply to anyone: physical functioning, pain, fatigue, mood, role limitation 2. Its principal advantage is comparability: a sample can be placed against population norms, compared across conditions and pooled with studies in other diseases. Its principal limitation is sensitivity: because generic items are written to apply widely, they often change less than a condition-specific item in response to a real clinical change 15,24.
A condition-specific instrument asks about the matters relevant to one disease, such as breathlessness on a defined task, joint stiffness on waking or the particular side-effect burden of one treatment class. It is usually more responsive within that condition, and its items are more credible to clinicians in the field. Its limitation is that the score has no meaning outside the condition and cannot be compared with other measures.
In practice, the decision is not a binary one. A common and defensible design combines one generic measure for comparability with one condition-specific measure as the responsive outcome, with one of them named as primary. It is not defensible to collect both and decide afterwards which to report as primary. The primary PRO and its timepoint should be named in the protocol.
Profile and index measures and their analytical implications
This axis cuts across the others and is the one most often overlooked. A profile instrument yields several domain scores that are reported separately — physical, emotional, social — and deliberately does not combine them, on the grounds that a trade-off between domains is a value judgement the instrument should not make for the respondent. A profile can localise an effect: it can show that an intervention improved physical functioning while leaving mood unchanged.
An index instrument yields a single score, usually by applying weights elicited from a population to each possible health state. Because the weights encode how much worse one state is than another, the single number can be used as a utility and entered into a quality-adjusted life-year (QALY) calculation. An index can enter an economic model; a profile cannot, and converting one into the other retrospectively by summing or averaging domain scores is not a legitimate substitute.
The practical consequence is that, if there is any possibility that a study will be used in a cost-effectiveness analysis, a health-technology appraisal or a reimbursement submission, a preference-based index measure must be included in the protocol from the outset. Adding one later requires a new round of data collection. Streiner and Norman, in Health measurement scales, and de Vet and colleagues, in Measurement in medicine, both treat this as a design decision rather than a scoring detail, which is the appropriate classification 15,24. If an economic endpoint is planned, it should be discussed with the team responsible for the study’s biostatistics before the protocol is locked.
Fixed questionnaires, item banks and computer-adaptive testing
The third axis is about administration. A fixed-length instrument presents every respondent with the same items in the same order. Scores are simple sums or transformed sums, every participant answers everything, and the measurement is easy to describe. The trade-off is that a fixed set of items measures precisely only over the part of the range its items cover, and it spends respondent effort on items that carry little information for that particular person.
An item bank approach calibrates a large pool of items onto a common scale, so different subsets of items can produce scores on that same scale 19. Administered adaptively, the software selects the next item based on the answers so far, stopping when a target precision is reached. The result is a shorter questionnaire with comparable or better precision, and scores that remain comparable even when two respondents answered different items. Cella and colleagues, in the Journal of Clinical Epidemiology, reported PROMIS developing and testing its first wave of adult self-reported health outcome item banks over 2005 to 2008, which is the best-known implementation of this approach 19.
Three cautions apply before adoption. Adaptive administration requires functioning software at every site, which is a question of feasibility and not only of measurement. The scoring cannot be reproduced by a reader from the published tables, so the calibration and the scoring engine used, including its version, must be reported. Finally, a short form drawn from a bank is not the same instrument as the full bank, and the form administered should be stated.
The three choices and the cost of each
| Axis | Option | What it buys | What it costs |
|---|---|---|---|
| Population coverage | Generic | Comparison across conditions and against population norms | Lower responsiveness to change within one condition |
| Condition-specific | Items clinicians recognise; usually more responsive | Score is not comparable outside the condition | |
| Score structure | Profile | Localises the effect to specific domains | Cannot be used as a utility in an economic model |
| Index | Single preference-weighted score usable for QALYs | Cannot show which domain changed | |
| Administration | Fixed-length | Simple, reproducible scoring; no software dependency | Precise only over the range its items cover |
| Item bank / adaptive | Shorter administration at comparable precision; scores comparable across different item subsets | Requires calibration and scoring software; results not reproducible from the printed tables |
Definitions as used in the measurement literature cited on this page, principally de Vet and colleagues, Measurement in medicine; Streiner and Norman, Health measurement scales; and, for item banks, Cella and colleagues in the Journal of Clinical Epidemiology. The table is a decision aid, not a quality ranking: none of these options is better than its alternative in the abstract.
Selection of an existing instrument
An established procedure exists for instrument selection, and it is not a literature search for “validated questionnaire”. Prinsen and colleagues set out in Trials a practical guideline for selecting outcome measurement instruments for outcomes in a core outcome set, and the same group’s COSMIN guideline for systematic reviews of outcome measurement instruments, in Quality of Life Research, describes how to appraise the candidate instruments identified 8,9. Valderas and colleagues’ EMPRO tool, in Value in Health, offers a standardised appraisal format where a full review is out of scope 23. Reeve and colleagues’ ISOQOL minimum standards, also in Quality of Life Research, give a defensible floor for what a PROM used in comparative effectiveness research should have demonstrated 10.
In practice, the sequence is as follows: the construct and the population are each defined in one sentence; existing instruments for that construct are identified; the author checks whether a systematic review of measurement properties has already been published for it, since such a review obviates a new appraisal; content validity in the study population is appraised first, followed by the remaining properties and then feasibility 1,5. Feasibility is assessed last but is not a formality: licensing cost, translation availability, administration time and electronic capture can each rule out otherwise suitable instruments.
The order is important: content validity is assessed first and feasibility last, and the construct is defined before either. When feasibility is decided first, studies tend to adopt an instrument that was easy to obtain but measures something adjacent to the research question.
Limitations of instrument catalogues
Two gaps in the evidence base should be stated explicitly rather than obscured.
The first is that existence is not evidence of adequacy. Chiarotto and colleagues, in the Journal of Clinical Epidemiology, reviewed patient-reported instruments for physical functioning in low back pain — a well-resourced, heavily studied area — and concluded that the content validity of those instruments required investigation, because it had largely not been investigated 4. If content validity is insufficiently evidenced in that area, it should be assumed to be insufficiently evidenced in other fields unless this has been checked. The COSMIN taxonomy, agreed by Mokkink and colleagues in the Journal of Clinical Epidemiology, provides the vocabulary for stating precisely which properties are and are not established; it is preferable to write “structural validity has not been examined in this population” than to allow a reader to infer that it has 18.
The second is that use in research is not use in care. Of the 315 instruments Churruca and colleagues identified, 270 (85.7%) were used in subsequent research, 51 (16.2%) had any online report of clinical or policy use, and 45 had no evidence of subsequent use at all 2. The field produces measures faster than it adopts them. If part of a study’s rationale is that the instrument will inform practice, that claim requires its own supporting evidence; the existence of the instrument does not provide it.
Reporting instrument selection in the methods section
A reviewer reading the methods section should be able to establish four points without consulting other sources: the construct measured, the exact version of the instrument used, the recall period, and the evidence that the instrument is appropriate for this population and this purpose. Most PRO methods paragraphs address the second point and leave the other three to be taken on trust.
The remedy is brief, and it is the same whether the instrument is generic or specific, profile or index, fixed or adaptive: the version and the scoring direction should be named, the recall window stated, the validation evidence cited in a comparable population, and what is not established should be stated. This last element requires only one clause but adds considerable credibility, because it shows the reviewer that the author has read the psychometric literature rather than only the instrument’s own documentation. The same discipline applies at the editing stage: when a manuscript undergoes scientific editing, the instrument paragraph is one of the places where careful reading can detect an unintended claim.
The same instrument, described two ways
Asks to be trusted
Quality of life was assessed using a validated disease-specific questionnaire. Higher scores indicate better quality of life. The questionnaire has been shown to be reliable and valid in previous studies.
Which instrument, and which version? “A validated disease-specific questionnaire” cannot be looked up, and self-report, proxy and observer versions of the same instrument are different measures.
Validated for what, and in whom? “Reliable and valid” names no property and no population. Validity is a property of an instrument in a population for a purpose, not a permanent attribute.
What was the recall period? Unstated, so the reader cannot tell what window the score describes or whether it matches the visit schedule.
Is this a profile or an index? Unstated, so the reader cannot tell whether the result could support an economic analysis or localise the effect.
Can be judged
The primary patient-reported outcome was condition-specific physical functioning, measured with the self-report version of [instrument], 20 items, 7-day recall, scored 0–100 with higher scores indicating better functioning. We selected it after identifying candidate instruments for this construct and appraising them against the COSMIN taxonomy; it was the only candidate with content-validity evidence elicited from patients in our target population and with published structural validity and test-retest reliability in a comparable sample. Cross-cultural validation in our setting has not been reported, and we treat between-country comparison as exploratory. A generic index measure was administered alongside it to support the planned economic analysis, and is reported as a secondary outcome.
Instrument, version, item count, recall period and scoring direction are all stated, so the measure is identifiable.
The selection process is described, so the choice can be challenged on its reasoning rather than assumed to be arbitrary.
The specific properties established are named — content validity, structural validity, test-retest reliability — rather than summarised as “valid”.
What is not established is stated, and the analysis is scoped accordingly rather than left for a reviewer to notice.
The profile/index distinction is handled explicitly, with the index measure in place before the economic analysis needs it.
The second version is longer, but every added clause answers a question that a reviewer would otherwise raise as an objection. More importantly, the second version cannot be written after data collection: the recall period, the version administered and the presence of an index measure were all fixed when the protocol was finalised. The paragraph therefore tests whether the measurement decisions were made deliberately.
Key points
Key points
Candidate instruments already exist for almost every PRO research question: Churruca and colleagues identified 315 from 6,453 screened citations, of which only 39 were generic. The first task is therefore selection rather than creation. Three choices are decisive (generic or condition-specific, profile or index, fixed-length or item bank), and each constrains later options; the profile/index choice in particular determines whether the data can ever support an economic analysis. Candidates should be appraised against the COSMIN taxonomy, with content validity assessed first and feasibility last, and the report should state which properties are established and which are not. The existence of an instrument does not establish its adequacy, and use in research does not constitute use in care.
Application to your study
Application to your study
- The construct and the population should each be defined in a single sentence before any instrument is examined. Without these definitions, the instrument search is unlikely to converge.
- A systematic review of measurement properties should be sought first. Where such a review exists for the construct, it has already undertaken the appraisal and identifies the evidence gaps.
- The feasibility of an economic endpoint should be decided at the outset. If such an endpoint is planned, a preference-based index measure must be specified in the protocol, because it cannot be added retrospectively.
- Content validity in the study population should be assessed before any other property. A high reliability coefficient for the wrong construct has no value, and Chiarotto and colleagues show that content validity is frequently the property left unexamined.
- The primary PRO and its timepoint should be named in the protocol. Collecting both a generic and a condition-specific measure and selecting one afterwards creates a reporting problem.
- The exact version and language to be administered should be confirmed — self-report versus proxy, full form versus short form, and the availability of a validated translation for the study setting.
- Licensing, translation and administration time should be resolved before the protocol is finalised. Feasibility is appraised last, but it retains a veto.
- The limitation corresponding to any identified evidence gap should be reported. Where cross-cultural or structural validity is unreported, this should be stated and the scope of the analysis adjusted accordingly.
Frequently asked questions
A patient-reported outcome is the attribute being measured: in the FDA’s phrasing, the aspect of health reported directly by the patient without interpretation by anyone else. A patient-reported outcome measure is the instrument used to measure it. The distinction matters in writing because journals and reviewers increasingly expect authors to name the construct separately from the questionnaire: “we measured condition-specific physical functioning using [instrument]” rather than “we measured [instrument]”. It also guards against unacknowledged substitution. If the available validated instrument measures a slightly different construct from the one in the research question, that is a limitation to be stated, not a wording problem to be concealed.
The two types answer different questions, so the choice follows from the claim to be made. A generic measure permits comparison across conditions and against population norms; a condition-specific measure is usually more responsive to change within the condition and more credible to clinicians in that field. Generic instruments are the scarcer resource: Churruca and colleagues, in Health Expectations, found that only 39 of 315 instruments were generic. A common and defensible approach is to administer one of each, with one named as primary in the protocol. It is not defensible to collect both and decide, after the results are known, which to report as the primary outcome.
Because a quality-adjusted life-year calculation requires a single number that encodes how much worse one health state is than another, and a profile measure deliberately does not supply one. A profile reports domain scores separately on the grounds that trading physical functioning against mood is a value judgement the instrument should not make on the respondent’s behalf. An index measure applies weights elicited from a population to each health state, which is precisely the judgement that an economic model requires. Summing or averaging a profile’s domains afterwards does not produce a utility, because the resulting number carries no information about relative preference. If an economic analysis is plausible, an index measure should be included in the protocol.
Its appropriateness must be checked, and the evidence is usually found to be partial. “Validated” is not a permanent property of an instrument; Messick argued in American Psychologist that validity attaches to an instrument used in a population for a purpose. In practice, authors should look for a systematic review of measurement properties for the construct; appraise candidates against the COSMIN taxonomy, which organises instrument quality into 3 domains, 7 measurement properties and 4 aspects; and establish content validity in the study population before any other property. Gaps should be expected. Churruca and colleagues found development heavily concentrated in a few countries, with 147 instruments (46.8%) from the United States and 81 (25.8%) from the United Kingdom, so cross-cultural evidence is often absent. Such an absence should be reported as a limitation.
Not without consequences that must be reported. Removing items changes the construct that the total score represents, and the cited validation evidence was generated for the full instrument, not for the modified version. Rothman and colleagues, in Value in Health, set out the position of the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) task force on using existing PRO instruments and modifying them; the practical implication is that modification obliges the investigator to re-establish the properties that the modification could have affected, at minimum content validity and structural validity. If respondent burden is the underlying problem, a short form published and calibrated by the instrument’s developers, or an item-bank measure administered adaptively, is the appropriate solution.
An item bank calibrates many items onto one scale, so that scores from different item subsets remain comparable. Under adaptive administration, software selects each subsequent item on the basis of previous answers and stops when a target precision is reached, yielding shorter questionnaires at comparable precision. Cella and colleagues, in the Journal of Clinical Epidemiology, described the development and testing by PROMIS of its first wave of adult item banks over 2005 to 2008. An item bank is warranted where respondent burden is a genuine constraint across a wide severity range. It is unnecessary for a small single-site study in which a fixed short form suffices, and it entails real costs: functioning software at every site, and scoring that a reader cannot reproduce from the published tables, so the calibration and scoring engine version must be reported.
No, and the published evidence is more limited than it appears. Chiarotto and colleagues, in the Journal of Clinical Epidemiology, reviewed patient-reported instruments for physical functioning in low back pain — a large, well-funded field — and concluded that content validity required investigation because it had largely not been investigated. Adoption is also weaker than publication suggests: of 315 instruments, 270 (85.7%) appeared in later research but only 51 (16.2%) had any traceable clinical or policy use, and 45 had no evidence of subsequent use at all. Publication should be treated as the start of the appraisal rather than its conclusion, and the properties verified should be named rather than the instrument being described simply as validated.
Development is justified when a documented search, rather than an impression, shows that no existing instrument measures the required construct, and when the time and sample needed to do it properly are available. For most projects, development is out of scope: establishing content validity alone requires qualitative work with patients, and PROMIS took several years to develop and test its first wave of item banks. Modification of an existing instrument is sometimes an appropriate intermediate option, but it carries its own revalidation obligations. The companion page on developing and evaluating a PRO instrument covers both routes and the requirements of each.
References
- US Department of Health and Human Services, Food and Drug Administration (CDER, CBER, CDRH). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. read 9 October 2026. hhs.gov
- Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, Leahy CJ, Braithwaite J. Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expectations. 2021;24(4):1015-1024. doi:10.1111/hex.13254 read 9 October 2026. doi.org/10.1111/hex.13254
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. doi:10.1136/bmj.n71 read 9 October 2026. doi.org/10.1136/bmj.n71
- Chiarotto A, Ostelo RW, Boers M, Terwee CB. A systematic review highlights the need to investigate the content validity of patient-reported instruments for physical functioning in low back pain. Journal of Clinical Epidemiology. 2018;95:73-93. read 9 October 2026. link.springer.com
- Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Quality of Life Research. 2018;27:1159-1170. doi:10.1007/s11136-018-1829-0 read 9 October 2026. doi.org/10.1007/s11136-018-1829-0
- Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN risk of bias checklist for assessing the methodological quality of studies on the measurement properties of patient-reported outcome measures. Quality of Life Research. 2018. read 9 October 2026. link.springer.com
- Fujita MSL, Agustin-Lacruz MdC, Terra AL. Journals' guidelines about title, abstract and keywords: an overview of Information Science and Communication Science areas. European Science Editing. 2018;44(4):76-79. read 9 October 2026. europeanscienceediting.org.uk
- Prinsen CA, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of outcome measurement instruments. Quality of Life Research. 2017. read 9 October 2026. link.springer.com
- Prinsen CA, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a 'Core Outcome Set': a practical guideline. Trials. 2016;17(1):449. read 9 October 2026. link.springer.com
- Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research. 2013;22(8):1889-1905. read 9 October 2026. link.springer.com
- Magasi S, Ryan G, Revicki D, et al. Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Quality of Life Research. 2012;21(5):739-746. read 9 October 2026. link.springer.com
- Olshansky E, Lakes KD, Vaughan J, et al. Enhancing the construct and content validity of rating scales for clinical research. The International Journal of Education and Psychological Assessment. 2012;10(1):36-50. read 9 October 2026. link.springer.com
- Terwee CB, Mokkink LB, Knol DL, et al. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Quality of Life Research. 2012;21(4):651-657. read 9 October 2026. link.springer.com
- Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity: establishing and reporting the evidence in newly developed PRO instruments for medical product evaluation. Part 1: eliciting concepts for a new PRO instrument. Value in Health. 2011;14(8):967-977. read 9 October 2026. link.springer.com
- de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in medicine. Cambridge University Press. 2011. read 9 October 2026. link.springer.com
- Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Quality of Life Research. 2010;19(4):539-549. read 9 October 2026. link.springer.com
- Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Medical Research Methodology. 2010;10:22. read 9 October 2026. link.springer.com
- Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology. 2010;63(7):737-745. doi:10.1016/j.jclinepi.2010.02.006 read 9 October 2026. doi.org/10.1016/j.jclinepi.2010.02.006
- Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology. 2010;63(11):1179-1194. doi:10.1016/j.jclinepi.2010.04.011 read 9 October 2026. doi.org/10.1016/j.jclinepi.2010.04.011
- Sijtsma K. On the use, the misuse, and the very limited usefulness of Cronbach's alpha. Psychometrika. 2009;74(1):107-120. read 9 October 2026. link.springer.com
- Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Quality of Life Research. 2009;18(9):1263-1278. read 9 October 2026. link.springer.com
- Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value in Health. 2009;12(8):1075-1083. read 9 October 2026. link.springer.com
- Valderas JM, Ferrer M, Mendivil J, et al. Development of EMPRO: a tool for the standardized assessment of patient-reported outcome measures. Value in Health. 2008;11(4):700-708. read 9 October 2026. link.springer.com
- Streiner DL, Norman GR. Health measurement scales: a practical guide to their development and use. Oxford University Press. 2008. read 9 October 2026. link.springer.com
- Leidy NK, Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363-370. read 9 October 2026. link.springer.com
- Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology. 2007;60(1):34-42. read 9 October 2026. link.springer.com
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD read 9 October 2026. doi.org/10.1136/bmj.39335.541782.AD
- Vogt DS, King DW, King LA. Focus groups in psychological assessment: enhancing content validity by consulting members of the target population. Psychological Assessment. 2004;16(3):231-243. read 9 October 2026. link.springer.com
- Sollaci LB, Pereira MG. The Introduction, Methods, Results, and Discussion (IMRAD) structure: a fifty-year survey. Journal of the Medical Library Association. 2004;92(3):364-371. read 9 October 2026. genreacrossborders.uwaterloo.ca
- Aaronson N, Alonso J, Burnam A, et al. Assessing health status and quality-of-life instruments: attributes and review criteria. Quality of Life Research. 2002;11(3):193-205. read 9 October 2026. link.springer.com
- Lohr KN, Aaronson NK, Alonso J, et al. Evaluating quality-of-life and health status instruments: development of scientific review criteria. Clinical Therapeutics. 1996;18(5):979-992. read 9 October 2026. link.springer.com
- Cortina JM. What is coefficient alpha? An examination of theory and applications. Journal of Applied Psychology. 1993;78:98-104. read 9 October 2026. link.springer.com
- Messick S. Test validity and the ethics of assessment. American Psychologist. 1980;35:1012-1027. read 9 October 2026. link.springer.com
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences. Pubrica. https://pubrica.com/academy/artical/pro-instrument-and-its-types/
Pubrica Academy. “Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences.” Pubrica, 9 Oct. 2026, pubrica.com/academy/artical/pro-instrument-and-its-types/.
Pubrica Academy (2026) Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences. Pubrica. Available at: https://pubrica.com/academy/artical/pro-instrument-and-its-types/ (Accessed: 15 October 2026).
Pubrica Academy. “Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences.” Pubrica. October 9, 2026. https://pubrica.com/academy/artical/pro-instrument-and-its-types/
Pubrica Academy, ‘Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/artical/pro-instrument-and-its-types/> accessed 15 October 2026.
Pubrica Academy. Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/artical/pro-instrument-and-its-types/
Pubrica Academy, “Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/artical/pro-instrument-and-its-types/
@misc{pro_instrument_and_its_types_2026,
author = {{Pubrica Academy}},
title = {Selecting a Patient-Reported Outcome (PRO) Instrument: Instrument Types and Their Analytical Consequences},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/artical/pro-instrument-and-its-types/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
PRO instrument selection record
This record should be completed before the protocol is locked and then retained. The completed record supplies most of the methods paragraph, and it is also the document required when a reviewer asks why this instrument was chosen rather than a better-known one.
PRO INSTRUMENT SELECTION RECORD
Study: ______________________ Date: __________ Completed by: __________
1. WHAT AM I MEASURING
Construct, in one sentence: ______________________________________
Population, in one sentence: _____________________________________
Purpose (discriminate between people / detect change over time / both): ______
Is this the primary outcome? Y / N Timepoint(s): __________________
2. DOES SOMETHING ALREADY EXIST
[ ] Searched for a published measurement-properties systematic review
of this construct. Found: Y / N Reference: ______________________
[ ] Listed candidate instruments (aim for all, not the first three):
1. ____________________ 2. ____________________
3. ____________________ 4. ____________________
[ ] Checked whether a core outcome set exists for this condition
3. THE THREE TYPE DECISIONS
Generic / condition-specific / both ....... __________
If both, which is PRIMARY: __________
Profile / index ........................... __________
Is an economic or cost-utility analysis possible, now or later? Y / N
If Y, a preference-based INDEX measure must be in this protocol.
Fixed-length / short form / item bank ..... __________
If adaptive: software and version available at every site? Y / N
4. APPRAISAL OF THE CHOSEN INSTRUMENT (content validity first)
Exact name and version: __________________________________________
Self-report / proxy / observer version: __________
Number of items: ______ Recall period: ______ Scoring range: ______
Scoring direction (higher = better or worse): ______
Grouped as in the COSMIN taxonomy: three domains, the measurement
properties within them, and the aspects that sit under validity.
Evidence? In a comparable population?
DOMAIN: VALIDITY
Content validity (patient input) ..... ______ ______
aspect: face validity .............. ______ ______
Construct validity ................... ______ ______
aspect: structural validity ........ ______ ______
aspect: hypotheses testing ......... ______ ______
aspect: cross-cultural validity .... ______ ______
Criterion validity (if a gold standard exists) __ ______
DOMAIN: RELIABILITY
Internal consistency ................. ______ ______
Reliability (test-retest) ............ ______ ______
Measurement error / smallest detectable change __ ______
DOMAIN: RESPONSIVENESS
Responsiveness ....................... ______ ______
Not measurement properties, but record them anyway:
Interpretability (norms, minimal important change) __ ______
Feasibility (see section 5) .......... ______ ______
Properties NOT established, to be written as a limitation:
______________________________________________________________
5. FEASIBILITY (last, but it has a veto)
[ ] Licence terms and cost confirmed in writing
[ ] Validated translation available for every language in the study
[ ] Administration time acceptable for this visit schedule
[ ] Electronic capture mode validated, if used
[ ] Scoring algorithm obtained, including handling of missing items
6. MODIFICATION
Am I changing anything about the instrument (items, wording, response
options, recall period, mode)? Y / N
If Y, list the change and the property that must be re-established:
______________________________________________________________
(If you cannot re-establish it within this study, do not modify.)
7. METHODS SENTENCE (draft it here, then paste it)
______________________________________________________________
______________________________________________________________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s medical writing and biostatistics teams conduct instrument selection as a documented appraisal rather than a search. The teams identify candidate instruments for the construct, establish whether a review of measurement properties already exists, appraise which properties are and are not established in a comparable population, and draft the methods paragraph and the corresponding limitation. Where an economic endpoint is planned, the teams identify the profile-versus-index decision while it can still be changed.